Health inequities in SARS-CoV-2 infection, seroprevalence, and COVID-19 vaccination: Results from the East Bay COVID-19 study
Open Access
- 15 August 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (8) , e0000647
Abstract
Comprehensive data on transmission mitigation behaviors and both SARS-CoV-2 infection and serostatus are needed from large, community-based cohorts to identify COVID-19 risk factors and the impact of public health measures. We conducted a longitudinal, population-based study in the East Bay Area of Northern California. From July 2020-March 2021, approximately 5,500 adults were recruited and followed over three data collection rounds to investigate the association between geographic and demographic characteristics and transmission mitigation behavior with SARS-CoV-2 prevalence. We estimated the populated-adjusted prevalence of antibodies from SARS-CoV-2 infection and COVID-19 vaccination, and self-reported COVID-19 test positivity. Population-adjusted SARS-CoV-2 seroprevalence was low, increasing from 1.03% (95% CI: 0.50–1.96) in Round 1 (July-September 2020), to 1.37% (95% CI: 0.75–2.39) in Round 2 (October-December 2020), to 2.18% (95% CI: 1.48–3.17) in Round 3 (February-March 2021). Population-adjusted seroprevalence of COVID-19 vaccination was 21.64% (95% CI: 19.20–24.34) in Round 3, with White individuals having 4.35% (95% CI: 0.35–8.32) higher COVID-19 vaccine seroprevalence than individuals identifying as African American or Black, American Indian or Alaskan Native, Asian, Hispanic, two or more races, or other. No evidence for an association between transmission mitigation behavior and seroprevalence was observed. Despite >99% of participants reporting wearing masks individuals identifying as African American or Black, American Indian or Alaskan Native, Asian, Hispanic, two or more races, or other, as well as those in lower-income households, and lower-educated individuals had the highest SARS-CoV-2 seroprevalence and lowest vaccination seroprevalence. Results demonstrate that more effective policies are needed to address these disparities and inequities.Keywords
All Related Versions
Funding Information
- Open Philanthropy
- Mercatus Center
- UC Berkeley Innovative Genomics Institute
- UC Berkeley Center for Population Health
This publication has 23 references indexed in Scilit:
- Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020JAMA Internal Medicine, 2020
- Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the Latinx Population During Shelter-in-Place in San FranciscoClinical Infectious Diseases, 2020
- Cumulative incidence and diagnosis of SARS-CoV-2 infection in New YorkAnnals of Epidemiology, 2020
- COVID-19 and the impact of social determinants of healthThe Lancet Respiratory Medicine, 2020
- Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020JAMA, 2020
- Extending the Use and Prediction Precision of Subnational Public Opinion EstimationAmerican Journal of Political Science, 2017
- Community Mitigation Guidelines to Prevent Pandemic Influenza — United States, 2017MMWR. Recommendations and Reports, 2017
- Programming With Models: Writing Statistical Algorithms for General Model Structures With NIMBLEJournal of Computational and Graphical Statistics, 2017
- poLCA: AnRPackage for Polytomous Variable Latent Class AnalysisJournal of Statistical Software, 2011
- Public Health Interventions and SARS Spread, 2003Emerging Infectious Diseases, 2004